At 10 o'clock in the evening, Li Rui started the video on time and met Gilead Vice President Andrew Dickinson.

"Dear Li, hello!" Dickinson was over 60 years old but in good spirits. He has served as Gilead's executive vice president for more than ten years. The acquisition of Gilead's acquisition of triangle, which he presided over, can be called twenty-one.

The most classic and most successful pharmaceutical industry acquisition case in the first decade of the century.

Gilead was not as valuable as it is today. It had to spend three years of revenue to acquire Triangle, which was a life-and-death gamble for them.

As a result, Gilead won the bet and obtained the anti-AIDS drug Emtricitabine from Triangle. This drug has been one of Gilead's most important revenue sources until today, creating a net profit of more than 3 billion magnesium!

Perhaps because he tasted the sweetness of the acquisition, he heard that pharmaset has made breakthrough progress in the research and development of hepatitis C drugs, Gilead immediately sent Andrew, the acquisition master, like a cat who smelled the fishy smell.

"Hello, Mr. Dickinson." Li Rui's attitude towards the guests who gave money was naturally very enthusiastic.

The two of them exchanged a few greetings first, and Dickinson took the lead in getting to the point.

"Li, I heard from Fu that the company you invested in has made a breakthrough in the research on hepatitis C drugs. Can you tell me in detail?"

Li Rui put a clinical trial report provided by pharmaset in front of him and explained a few data according to the script.

Although the video quality is a bit vague, after Li Rui finished speaking the data, he could still see that Dickinson's face changed.

The data is so good!

"Wait, you just said, this drug can safely and effectively treat all types of hepatitis C without combining interferon? Overall sustained virological responses for hepatitis C in combination with polyethylene glycol interferon and ribavirin, for hepatitis C in type 1 and 4.

The rate (svr) reaches 90%; for hepatitis C type 22, the svr combined with ribavirin is 89% to 95%; for hepatitis C type 3, the svr combined with ribavirin

svr is more than 60%. Is this data OK?” Dickinson asked in disbelief.

No wonder he reacted like this. The data of this svr is too high and sounds like it is fake!

Li Rui said: "There is absolutely no problem, and all the reports of the trials can stand the investigation. So far, the results of the trial show that this drug can effectively treat hepatitis C virus infections in genes 1, 2, 3 and 4."

"My God." Dickinson subconsciously exclaimed, then realized his loss of composure and quickly changed his calm face.

"The drug is currently undergoing the final test of the second phase. After the second phase test is completed, the third phase test will be conducted immediately. If your company is interested, I will provide you with detailed data on the second phase test."

Li Rui said again.

Dickinson said: "If the data is true, I would like to ask Mr. Li, are you hoping to transfer the pharmaset shares and the new drug income rights you own?"

Li Rui smiled and said, "Maybe, maybe not. I don't like to say things to death. Although I am optimistic about the future market prospects of this medicine, everything in the world has a price, right?"

Dickinson said: "I agree with you. So if it is transferred, what are the prices you are expecting?"

Li Rui said: "I think Gilead knows better than me about how huge the hepatitis C market is. The analysis and judgment of the future market will definitely exceed my half-baked one in the pharmaceutical industry. My personal expectations are not important, what is important is that both of us can

Form a consensus on what price level.”

He seemed to say everything, but he seemed to say nothing.

Dickinson pondered for a moment and said, "Gilead needs to see all the data of the second phase clinical trial and do further analysis. I wonder if you agree?"

"No problem. When the experiment is completed, I will hand over the data to you for analysis immediately. However, I hope your company can propose a negotiated price before the third phase clinical trial, otherwise I have other options." Li Rui said.

“What are the choices you mean?”

"For example, AstraZeneca, Pfizer, Novartis, Roche, Sanofi, GlaxoSmithKline... I guess they will be very interested in such a drug." Li Rui said.

Dickinson hurriedly said: "Please rest assured that as long as we get enough analytical data, we will submit a quote for you as soon as possible."

"I hope our cooperation will succeed." Li Rui smiled.

In the video introduction, Li Rui chatted with Fu Shande for a few more words.

Fu Shande was so excited: "Li Rui, did you really get the medicine? I heard Andrew's meaning, the hepatitis C market is very large?"

Li Rui said: "Well, the anti-hepatitis C virus market has at least 70 to 80 billion magnesium."

After Gilead acquired pharmaset in his previous life, it officially launched sofosbuvir at the end of 2012. The sales exceeded 10 billion magnesium in the second year, helping it to enter the top ten pharmaceutical companies in the world.

In the following years, Sofosbuvir's sales were very gratifying, and the annual sales remained above 10 billion magnesium.

It was not until 2016 that due to the overwhelming efficacy of sofosbuvir, a large number of hepatitis C patients were cured, the number of patients was getting smaller and smaller, and the growth rate of the hepatitis C market slowed down, resulting in a significant decline in revenue.

Despite the short life cycle of Sofosbuvir, Gilead still profited more than 30 billion magnesium from this acquisition!

Hearing that the market is so huge, Fu Shande said in surprise: "Why don't you do it yourself? That's not the profitable more?"

Do it yourself?

Li Rui also wants to do it himself, but it is one thing to develop a new drug, and it is another thing to be able to mass produce, and marketing after mass production is another thing!

Sofosbuvir was sold to Gilead, and was run by this powerful mature pharmaceutical company to make so much money.

If it is replaced by pharmaset to operate, it may not be so successful.

Moreover, the chain of R&D, production and sales collection is too long, and Li Rui can't wait for that long.

He has to race against time, make quick money, and then invest money in other industries with long returns cycles to prepare for greater development in the future.

So Li Ruiming knew that the market was super huge. Even though he knew that it would allow Gilead to take advantage of it, he would not be able to do it himself. He had to make a profit as soon as possible.

Li Rui didn't explain much: "Old Fu, don't forget. Only when the acquisition is successful can you get the commission!"

According to the previous agreement between Li Rui and Fu Shande, if the purchase price is less than 10 billion magnesium, Fu Shande can get a commission of 0.01%. If the purchase price is between 10 billion and 11 billion, he can get a commission of 0.02.

A % commission of more than 11 billion can get a 0.03% commission!
Chapter completed!